Atlas Protocol · Clinical Prevention

Atlas Cardiovascular Module

56-gene cardiovascular panel: cardiomyopathies, arrhythmias, aortopathies.

A 56-gene cardiovascular module covering hypertrophic and dilated cardiomyopathies, channelopathies, and aortopathies.

GenDG §10

This is a predictive genetic test.

The order page will ask you to either book counseling or waive counseling in writing per German GenDG §10. Your choice is fully documented and accessible at any time.

HOW IT WORKS

How it works.

  1. 01

    Easy at-home test

    Order in three clicks, no login. Kit ships from Berlin within 5 working days.

  2. 02

    Get your report and personalized action plan

    Follow the guided sample collection. Your AI-interpreted clinical report arrives by secure email.

  3. 03

    Consult with professionals and retest

    Discuss findings with your physician or our medical geneticist; retest as your interventions evolve.

WHICH PART OF YOUR BODY

Which part of your body.

  • Heart muscle
  • Heart rhythm
  • Aorta
  • Blood vessels
  • Lungs
WHAT THIS PANEL ANSWERS

What this panel answers.

Do you carry inherited variants that raise your risk for cardiomyopathies, dangerous heart-rhythm conditions, or aortic disease?

WHAT CHANGES IF A FINDING IS IDENTIFIED

What changes if something is found.

  1. Carriers are referred for structured cardiology surveillance: echocardiogram and cardiac MRI on a defined cadence, plus Holter monitoring when a rhythm disorder is suspected.
  2. For specific high-risk channelopathy variants, an electrophysiologist evaluates whether an implantable cardioverter defibrillator (ICD) is indicated.
  3. Family cascade testing identifies relatives who may also benefit from surveillance.
  4. Lifestyle and competitive-sport recommendations are individualized per variant by the treating cardiologist.
Pathway references
  • GenDG §7
GENES ANALYZED

What is analyzed.

Atlas analyzes each gene in its entirety -- not just hotspot regions -- against current clinical literature. Findings are reviewed by a board-certified medical geneticist before release.

PRV02

Cardiovascular Diseases

56 genes

A 56-gene panel for inherited heart and vascular disease. Covers the major cardiomyopathy genes, the channelopathy genes that predispose to sudden cardiac arrest, and the connective-tissue genes that drive aortic-aneurysm syndromes such as Marfan and Loeys-Dietz.

Clinical areas covered
  • Cardiomyopathies -- hypertrophic, dilated, arrhythmogenic
  • Aortopathies -- Marfan, Loeys-Dietz, vascular Ehlers-Danlos
  • Channelopathies -- long QT, Brugada, CPVT
  • Familial pulmonary arterial hypertension
  • Hereditary hemorrhagic telangiectasia
Analyzed genes -- 56 genes
  • ACTA2
  • ACTC1
  • ACVRL1
  • ALPK3
  • BAG3
  • BMPR2
  • CALM1
  • CALM2
  • CALM3
  • CASQ2
  • CAV1
  • COL3A1
  • DES
  • DSC2
  • DSG2
  • DSP
  • EMD
  • ENG
  • FBN1
  • FHL1
  • FLNC
  • GDF2
  • KCNH2
  • KCNK3
  • KCNQ1
  • KDR
  • LAMP2
  • LMNA
  • LOX
  • MYBPC3
  • MYH11
  • MYH7
  • MYL2
  • MYL3
  • MYLK
  • PKP2
  • PLN
  • PRKAG2
  • RBM20
  • RYR2
  • SCN5A
  • SMAD3
  • SMAD9
  • TBX4
  • TECRL
  • TGFB2
  • TGFBR1
  • TGFBR2
  • TMEM43
  • TNNC1
  • TNNI3
  • TNNT2
  • TPM1
  • TRDN
  • TTN
  • TTR

Gene list per CeGaT PRV02 (2026-05).

WHY THIS MATTERS

Why early knowledge matters.

  • PRV02

    Cardiovascular Diseases

    Vascular disease can develop quietly over years, and inherited cardiac conditions are often discovered only after a serious event. An identified variant lets a cardiologist start surveillance (echocardiogram, ECG, MR imaging, aortic-root monitoring) before structural change appears, and informs decisions about exercise, anesthesia, and medications.

RESULT INTERPRETATION

How findings are reported.

Every Atlas predictive report uses the same five-outcome framework so you and your physician can read it the same way each time.

  1. 01

    Pathogenic variant

    Increased disease risk. The report includes an individualized prevention plan and a recommendation to discuss next steps with a physician or medical geneticist.

  2. 02

    Likely pathogenic variant

    Probable disease association. Preventive monitoring is typically justified; the strength of evidence is documented in the report.

  3. 03

    Variant of uncertain significance (VUS)

    Reported but not currently actionable. A VUS may be reclassified over time as new evidence accumulates -- Atlas does not act on VUS findings without specialist review.

  4. 04

    No relevant variant in this panel

    No pathogenic or likely-pathogenic variant was identified in the analyzed genes. This does not eliminate all genetic risk -- only the genes in this panel were assessed.

  5. 05

    Family implications

    When an actionable variant is found, cascade testing of first-degree relatives is typically recommended -- a decision made together with a counselor.

Module-specific implications
  • PRV02

    Cardiovascular Diseases

    • Channelopathy findings (KCNQ1, KCNH2, SCN5A, RYR2) can change which drugs are safe and inform exercise guidance.
    • Aortopathy findings (FBN1, TGFBR1/2, COL3A1) typically trigger imaging surveillance and, in some cases, early surgical planning.
    • Cardiomyopathy findings often warrant first-degree-relative screening -- the condition can be present without symptoms.
Counseling and cascade testing

Predictive genetic testing in Germany requires consultation with a physician qualified in human genetics under §7 of the GenDG (Arztvorbehalt). Atlas Counseling provides this before and after the test. When an actionable finding has implications for relatives, your counselor will discuss cascade testing -- not Atlas alone.

CLINICAL LIMITATIONS

What this test does not do.

  • Not a diagnosis of active disease

    A variant indicates predisposition. It does not confirm a condition is currently present.

  • Does not replace screening or routine care

    Imaging, lab work, and physical examination remain part of clinical care. Atlas results inform them; they do not substitute for them.

  • Not all risk is genetic

    Environment, behavior, age, and chance contribute to most common conditions. A genetic test reads one input.

  • A negative result does not eliminate risk

    Only the genes on the panel were analyzed. Variants in other genes, in non-coding regions, and outside the assay's technical scope are not assessed.

  • Clinical decisions remain with your physician

    Atlas reports are designed to be reviewed with a physician or medical geneticist. We do not recommend acting on a finding without that conversation.

GenDG §7

Predictive panels on this page are GenDG §7 Arztvorbehalt: counseling with a qualified human-genetics physician is required before and after the test. Atlas Counseling is included in the order flow.

Ready to start? €590 · 3–4 weeks after sample arrival

Order →

Not sure if this is the right protocol? Let Atlas walk you through a few questions. Start Triage →

Or browse all 24 protocols: Open the Console →

Not ready? Book a counseling session first →

Already have your genome with Atlas?

See Atlas Baseline